Mammogen CEO Featured on ASBN Discussing the Future of Breast Cancer Screening

BioSpace | October 27, 2026 Mammogen has announced a clinical research partnership with MammoLink, a specialized women's health imaging provider, to expand community access to innovative breast cancer detection technologies. Through this collaboration, MammoLink will participate in Mammogen's KATELYN-ERIN clinical trial, a prospective study involving approximately 2,600 women. The partnership will leverage MammoLink's mobile 3D mammography network across Florida to evaluate Mammogen's genTRU-breast™ blood-based RNA assay alongside traditional breast imaging. The initiative represents an important step toward integrating molecular diagnostics with community-based breast care, with the goal of improving accessibility and supporting earlier breast cancer detection, particularly for women with dense breast tissue. Click Here to Read the Full Article on BioSpace

BioSpace | October 20, 2026 Mammogen announced the appointment of Rebecca D. Kaltman, M.D., Executive Director of the Inova Saville Cancer Screening and Prevention Center, as Principal Investigator for its KATELYN-ERIN clinical trial. The study will evaluate genTRU-breast™, Mammogen's RNA-powered blood-based assay being developed to support earlier breast cancer detection, particularly for women with dense breast tissue. Dr. Kaltman brings 20 years of experience in oncology, cancer prevention, and clinical research. Her leadership marks an important step as Mammogen advances its clinical validation efforts and explores how blood-based diagnostics can complement traditional breast imaging. Click Here to Read the Full Press Release →